Keywords: Tumors (Post-Treatment), Spectroscopy, Tumor, Drugs, Hyperpolarized MR (Non-Gas)
Motivation: Inhibiting TERT or its upstream transcription factor GABPB1 can result in tumor growth inhibition. Inhibiting EGFR, upstream of TERT, can also reduce TERT expression.
Goal(s): Investigating the combined effects of EGFR and TERT inhibition and assessing whether our MRS-based biomarkers can detect the impact of this combination therapy in cell and animal models.
Approach: Proton and hyperpolarized 13C spectroscopy in cell and animal models
Results: Enhanced inhibition of both cell and tumor growth was observed in our GBM models when TERT/GABPB1 and EGFR were targeted simultaneously. This was associated with a drop in hyperpolarized lactate production from pyruvate.
Impact: This study identifies HP lactate as a metabolic biomarker of response to the dual TERT/GABPB1 and EGFR inhibition in cells and animals and points to the value of this biomarker in detecting the added value of this novel combination therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords